{"DataElement":{"publicId":"5089211","version":"1","preferredName":"Patient Strong CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria Last Date","preferredDefinition":"The date related to the last administration of CYP2C8/CYP3A inhibitors for clinical trial eligibility determination.","longName":"CYPDT","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"4473475","version":"1","preferredName":"Patient Strong CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Having strength, power, or intensity greater than average or expected._Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids._This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics._The act of bringing about something._The interference with or prevention of an action or response even though the stimulus for that action or response is present._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:4473473v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4473473","version":"1","preferredName":"Strong CYP3A Gene Locus CYP2C8 Gene Induction Inhibition Clinical Trial Eligibility Criteria","preferredDefinition":"Having strength, power, or intensity greater than average or expected.:Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids.:This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics.:The act of bringing about something.:The interference with or prevention of an action or response even though the stimulus for that action or response is present.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"4473473v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strong","conceptCode":"C62223","definition":"Having strength, power, or intensity greater than average or expected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"CYP3A Gene Locus","conceptCode":"C107557","definition":"Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"CYP2C8 Gene","conceptCode":"C46071","definition":"This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inhibition","conceptCode":"C42791","definition":"The interference with or prevention of an action or response even though the stimulus for that action or response is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"022C94FC-EFD2-2F3F-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"ONEDATA","dateModified":"2014-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"022C94FC-EFE3-2F3F-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2192181","version":"1","preferredName":"Last Date","preferredDefinition":"the last date of an evaluation, assessment, or treatment.","longName":"LAST_DT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"mm/dd/yyyy","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208025","version":"1","preferredName":"Last Date","preferredDefinition":"Coming after all others in time or space or degree or being the only one remaining.:a particular day specified as the time something has, or will, happen.","longName":"C25551:C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Last","conceptCode":"C25551","definition":"Coming after all others in time or space or degree or being the only one remaining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3957-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E90113A5-47AF-142F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-16","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Date last received","type":"Preferred Question Text","description":"Date last received","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"271E03B5-7573-99A7-E050-BB89AD431778","latestVersionIndicator":"Yes","beginDate":"2015-12-17","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-12-17","modifiedBy":"ZIEGLERK","dateModified":"2015-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}